Feature Article: The GLP-1 revolution, the good the bad and the ugly

If it feels like your practice is increasingly dominated by patients asking for the "miracle jab," you aren’t alone.

MHRA Safety Update: Semaglutide and the Risk of Rare Vision Loss

If you prescribe semaglutide, you need to know about this.

The latest evidence (2025–2026) on the benefits and risks of Menopausal HRT

Individualized HRT offers substantial symptomatic relief with acceptable safety when used appropriately; however, ongoing research is needed to address persistent uncertainties about long-term outcomes across diverse populations and evolving therapeutic options.

RARE DISEASE IN UK PRIMARYCARE: WHY “MORE EDUCATION”ISN’T ENOUGH

SGLT2i vs. GLP-1 RA: WHICH ONE OFFERS MORE KIDNEY PROTECTION?

Both SGLT2 inhibitors and GLP-1 receptor agonists protect the kidneys in type 2 diabetes. We know that. But nobody has run a head-to-head trial to tell us which one does it better.A large new study published in JAMA is the closest we have got to an answer - the results are not as straightforward as you might expect...

It shouldn't be this hard!

What the RCGP and Patients Association report means for GP workload, referrals, and NHS digital systems

The first first large-scale comparative data: SGLT-2i vs. GLP-1 RA for kidney outcomes

PLUS: a year of NICE guideline changes, HRT evidence reviewed, and rare disease in UK primary care.

GLP-1 Receptor Agonists: Mechanism of Action

How GLP-1 receptor agonists drive weight loss across the brain, gut, and metabolism

NICE IS ABOUT TO PRESCRIBE MORE MEDICINES - HERE'S WHY

For 26 years, NICE has used the same yardstick to decide whether a new medicine is worth funding: the cost-effectiveness threshold. From April 2026, that yardstick is changing for the first time, and prescribers will feel it.

Only 61% of Children in One London Borough Are Fully Vaccinated by Age 5

Childhood vaccination is supposed to be one of the most straightforward wins in public health. But a new study published in the BJGP reveals just how far uptake has fallen in some of the UK’s most diverse communities.

IS IT SCIENCE FICTION? THE NHS JUST TESTED A REAL-LIFE TRICORDER

In Star Trek, Dr McCoy could diagnose any condition by waving a handheld tricorder over a patient. No blood tests. No waiting lists. Just an instant readout. However, Imperial College London just published the results of a trial called, yes, TRICORDER.

The prescription conversation that just got more structured

Prescribing gabapentinoids, benzos and Z-drugs? The ending comes first now.

The safety circuit breaker: Redefining the diagnostic journey

The mandate is clear: If a diagnosis remains unsubstantiated or symptoms escalate after three appointments: Reflect, Review, and Rethink. - Jess's Rule. Three strikes and we rethink.

Art The art of "Diagnostic Elegance": Refocusing the hypertension review

Recent evidence suggests that we are 'over-testing' our hypertension patients, says report from BJGP

Metformin monotherapy is over 💊

PLUS: an AI stethoscope trial across 205 practices; semaglutide flagged for vision loss; and NICE changes its cost-effectiveness threshold for the first time since 1999.

Are We Losing the Battle for Primary Care?

Where is the money really flowing in healthcare...

The first first large-scale comparative data: SGLT-2i vs. GLP-1 RA for kidney outcomes

PLUS: a year of NICE guideline changes, HRT evidence reviewed, and rare disease in UK primary care.